Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2018

01-09-2018 | Review

New emerging roles of microRNAs in breast cancer

Authors: Edna Ayerim Mandujano-Tinoco, Alfredo García-Venzor, Jorge Melendez-Zajgla, Vilma Maldonado

Published in: Breast Cancer Research and Treatment | Issue 2/2018

Login to get access

Abstract

Background

MicroRNAs constitute a large family of non-coding RNAs, which actively participate in tumorigenesis by regulating a set of mRNAs of distinct signaling pathways. An altered expression of these molecules has been found in different tumorigenic processes of breast cancer, the most common type of cancer in the female population worldwide.

Purpose

The objective of this review is to discuss how miRNAs become master regulators in breast tumorigenesis.

Methods

An integrative review of miRNAs and breast cancer literature from the last 5 years was done on PubMed. We summarize recent works showing that the defects on the biogenesis of miRNAs are associated with different breast cancer characteristics. Then, we show several examples that demonstrate the link between cellular processes regulated by miRNAs and the hallmarks of breast cancer. Finally, we examine the complexity in the regulation of these molecules as they are modulated by other non-coding RNAs and the clinical applications of miRNAs as they could serve as good diagnostic and classification tools.

Conclusion

The information presented in this review is important to encourage new directed studies that consider microRNAs as a good tool to improve the diagnostic and treatment alternatives in breast cancer.
Literature
1.
Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843–854PubMedCrossRef
2.
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65(16):7065–7070PubMedCrossRef
3.
4.
5.
Borchert GM, Lanier W, Davidson BL (2006) RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 13(12):1097–1101PubMedCrossRef
6.
Bordinhao AL, Evangelista AF, Oliveira RJ, Macedo T, Silveira HC, Reis RM, Marques MM (2016) MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib. Oncol Rep 36(6):3197–3206PubMedCrossRef
7.
Koo CX, Kobiyama K, Shen YJ, LeBert N, Ahmad S, Khatoo M, Aoshi T, Gasser S, Ishii KJ (2015) RNA polymerase III regulates cytosolic RNA:DNA hybrids and intracellular microRNA expression. J Biol Chem 290(12):7463–7473PubMedPubMedCentralCrossRef
8.
Poursadegh Zonouzi AA, Shekari M, Nejatizadeh A, Shakerizadeh S, Fardmanesh H, Poursadegh Zonouzi A, Rahmati-Yamchi M, Tozihi M (2017) Impaired expression of Drosha in breast cancer. Breast Dis 37:55PubMedCrossRef
9.
Fardmanesh H, Shekari M, Movafagh A, Shargh SA, Zonouzi AAP, Shakerizadeh S, Zonouzi AP, Hosseinzadeh A (2016) Upregulation of the double-stranded RNA binding protein DGCR8 in invasive ductal breast carcinoma. Gene 581(2):146–151PubMedCrossRef
10.
Dedes KJ, Natrajan R, Lambros MB, Geyer FC, Lopez-Garcia MA, Savage K, Jones RL, Reis-Filho JS (2011) Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer 47(1):138–150PubMedCrossRef
11.
Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, Spizzo R, Fernandez AF, Davalos V, Villanueva A, Montoya G et al (2010) A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 18(4):303–315PubMedCrossRef
12.
Vaidyanathan S, Thangavelu PU, Duijf PH (2016) Overexpression of Ran GTPase components regulating nuclear export, but not mitotic spindle assembly, marks chromosome instability and poor prognosis in breast cancer. Target Oncol 11(5):677–686PubMedCrossRef
13.
Kwon SY, Lee JH, Kim B, Park JW, Kwon TK, Kang SH, Kim S (2014) Complexity in regulation of microRNA machinery components in invasive breast carcinoma. Pathol Oncol Res 20(3):697–705PubMedCrossRef
14.
Spoelstra NS, Cittelly DM, Christenson JL, Gordon MA, Elias A, Jedlicka P, Richer JK (2016) Dicer expression in estrogen receptor-positive versus triple-negative breast cancer: an antibody comparison. Hum Pathol 56:40–51PubMedPubMedCentralCrossRef
15.
Sha LY, Zhang Y, Wang W, Sui X, Liu SK, Wang T, Zhang H (2016) MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer. Eur Rev Med Pharmacol Sci 20(11):2201–2208PubMed
16.
Melo SA, Sugimoto H, O’Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA et al (2014) Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 26(5):707–721PubMedPubMedCentralCrossRef
17.
Breving K, Esquela-Kerscher A (2010) The complexities of microRNA regulation: mirandering around the rules. Int J Biochem Cell Biol 42(8):1316–1329PubMedCrossRef
18.
Yang JS, Phillips MD, Betel D, Mu P, Ventura A, Siepel AC, Chen KC, Lai EC (2011) Widespread regulatory activity of vertebrate microRNA* species. RNA 17(2):312–326PubMedPubMedCentralCrossRef
19.
Rhodes LV, Martin EC, Segar HC, Miller DF, Buechlein A, Rusch DB, Nephew KP, Burow ME, Collins-Burow BM (2015) Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. Oncotarget 6(18):16638–16652PubMedPubMedCentralCrossRef
20.
Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, Kim NH, Dhanasekaran SM, Chinnaiyan AM, Athey BD (2009) New class of microRNA targets containing simultaneous 5′-UTR and 3′-UTR interaction sites. Genome Res 19(7):1175–1183PubMedPubMedCentralCrossRef
21.
22.
Chapat C, Jafarnejad SM, Matta-Camacho E, Hesketh GG, Gelbart IA, Attig J, Gkogkas CG, Alain T, Stern-Ginossar N, Fabian MR et al (2017) Cap-binding protein 4EHP effects translation silencing by microRNAs. Proc Natl Acad Sci USA 114(21):5425–5430PubMedCrossRef
23.
Ramchandran R, Chaluvally-Raghavan P (2017) miRNA-mediated RNA activation in mammalian cells. Adv Exp Med Biol 983:81–89PubMedCrossRef
24.
Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S (2007) The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 67(22):11001–11011PubMedCrossRef
25.
Zhu S, Si ML, Wu H, Mo YY (2007) MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282(19):14328–14336PubMedCrossRef
26.
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J et al (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131(6):1109–1123PubMedCrossRef
27.
Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO et al (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8(10):R214PubMedPubMedCentralCrossRef
28.
Liang Z, Wu H, Reddy S, Zhu A, Wang S, Blevins D, Yoon Y, Zhang Y, Shim H (2007) Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem Biophys Res Commun 363(3):542–546PubMedCrossRef
29.
Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J (2008) hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14(5):1340–1348PubMedCrossRef
30.
31.
Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251(3):499–505PubMedCrossRef
32.
33.
Di Leva G, Piovan C, Gasparini P, Ngankeu A, Taccioli C, Briskin D, Cheung DG, Bolon B, Anderlucci L, Alder H et al (2013) Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet 9(3):e1003311PubMedPubMedCentralCrossRef
34.
Li B, Lu Y, Wang H, Han X, Mao J, Li J, Yu L, Wang B, Fan S, Yu X et al (2016) miR-221/222 enhance the tumorigenicity of human breast cancer stem cells via modulation of PTEN/Akt pathway. Biomed Pharmacother 79:93–101PubMedCrossRef
35.
Dentelli P, Traversa M, Rosso A, Togliatto G, Olgasi C, Marchio C, Provero P, Lembo A, Bon G, Annaratone L et al (2014) miR-221/222 control luminal breast cancer tumor progression by regulating different targets. Cell Cycle 13(11):1811–1826PubMedPubMedCentralCrossRef
36.
Li Y, Liang C, Ma H, Zhao Q, Lu Y, Xiang Z, Li L, Qin J, Chen Y, Cho WC et al (2014) miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. Molecules 19(6):7122–7137PubMedCrossRef
37.
Han L, Liu B, Jiang L, Liu J, Han S (2016) MicroRNA-497 downregulation contributes to cell proliferation, migration, and invasion of estrogen receptor alpha negative breast cancer by targeting estrogen-related receptor alpha. Tumour Biol 37(10):13205–13214PubMedCrossRef
38.
Shen L, Li J, Xu L, Ma J, Li H, Xiao X, Zhao J, Fang L (2012) miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w. Exp Ther Med 3(3):475–480PubMedCrossRef
39.
Zhang Y, Zhang Z, Li Z, Gong D, Zhan B, Man X, Kong C (2016) MicroRNA-497 inhibits the proliferation, migration and invasion of human bladder transitional cell carcinoma cells by targeting E2F3. Oncol Rep 36(3):1293–1300PubMedCrossRef
40.
Liu J, Zhou Y, Shi Z, Hu Y, Meng T, Zhang X, Zhang S, Zhang J (2016) microRNA-497 modulates breast cancer cell proliferation, invasion, and survival by targeting SMAD7. DNA Cell Biol 35(9):521–529PubMedCrossRef
41.
Li XY, Luo QF, Wei CK, Li DF, Li J, Fang L (2014) MiRNA-107 inhibits proliferation and migration by targeting CDK8 in breast cancer. Int J Clin Exp Med 7(1):32–40PubMedPubMedCentral
42.
Zhang L, Ma P, Sun LM, Han YC, Li BL, Mi XY, Wang EH, Song M (2016) MiR-107 down-regulates SIAH1 expression in human breast cancer cells and silencing of miR-107 inhibits tumor growth in a nude mouse model of triple-negative breast cancer. Mol Carcinog 55(5):768–777PubMedCrossRef
43.
44.
Gao J, Li L, Wu M, Liu M, Xie X, Guo J, Tang H, Xie X (2013) MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS ONE 8(6):e65138PubMedPubMedCentralCrossRef
45.
Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O’Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T et al (2011) TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal 4(177):ra41PubMedCrossRef
46.
Hwang MS, Yu N, Stinson SY, Yue P, Newman RJ, Allan BB, Dornan D (2013) miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. PLoS ONE 8(6):e66502PubMedPubMedCentralCrossRef
47.
Ye X, Bai W, Zhu H, Zhang X, Chen Y, Wang L, Yang A, Zhao J, Jia L (2014) MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. BMB Rep 47(5):268–273PubMedPubMedCentralCrossRef
48.
Falkenberg N, Anastasov N, Schaub A, Radulovic V, Schmitt M, Magdolen V, Aubele M: Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221 (2015) Oncotarget 6(10):8103–8114PubMedPubMedCentralCrossRef
49.
Rostas JW 3rd, Pruitt HC, Metge BJ, Mitra A, Bailey SK, Bae S, Singh KP, Devine DJ, Dyess DL, Richards WO et al (2014) microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer. Mol Cancer 13:200PubMedPubMedCentralCrossRef
50.
Dobson JR, Taipaleenmaki H, Hu YJ, Hong D, van Wijnen AJ, Stein JL, Stein GS, Lian JB, Pratap J (2014) hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3. Cancer Cell Int 14:73PubMedPubMedCentralCrossRef
51.
Tavanafar F, Safaralizadeh R, Hosseinpour-Feizi MA, Mansoori B, Shanehbandi D, Mohammadi A, Baradaran B (2017) Restoration of miR-143 expression could inhibit migration and growth of MDA-MB-468 cells through down-regulating the expression of invasion-related factors. Biomed Pharmacother 91:920–924PubMedCrossRef
52.
Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S, Liu M, Gao X, Liu Y, Zhao C et al (2014) miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer 13:220PubMedPubMedCentralCrossRef
53.
Tang W, Yu F, Yao H, Cui X, Jiao Y, Lin L, Chen J, Yin D, Song E, Liu Q (2014) miR-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene 33(20):2629–2638PubMedCrossRef
54.
He T, Qi F, Jia L, Wang S, Song N, Guo L, Fu Y, Luo Y (2014) MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2. J Pathol 232(5):499–508PubMedCrossRef
55.
Jones R, Watson K, Bruce A, Nersesian S, Kitz J, Moorehead R (2017) Re-expression of miR-200c suppresses proliferation, colony formation and in vivo tumor growth of murine claudin-low mammary tumor cells. Oncotarget 8(14):23727–23749PubMedPubMedCentralCrossRef
56.
Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C et al (2013) Tumour angiogenesis regulation by the miR-200 family. Nat Commun 4:2427PubMedPubMedCentralCrossRef
57.
Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY et al (2014) Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 33(6):679–689PubMedCrossRef
58.
Hrdlickova R, Nehyba J, Bargmann W, Bose HR Jr (2014) Multiple tumor suppressor microRNAs regulate telomerase and TCF7, an important transcriptional regulator of the Wnt pathway. PLoS ONE 9(2):e86990PubMedPubMedCentralCrossRef
59.
Jiang S, Zhang LF, Zhang HW, Hu S, Lu MH, Liang S, Li B, Li Y, Li D, Wang ED et al (2012) A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J 31(8):1985–1998PubMedPubMedCentralCrossRef
60.
Xiao X, Huang X, Ye F, Chen B, Song C, Wen J, Zhang Z, Zheng G, Tang H, Xie X (2016) The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer. Sci Rep 6:21735PubMedPubMedCentralCrossRef
61.
Fong MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J, Chow A, O’Connor ST, Li S, Chin AR et al (2015) Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol 17(2):183–194PubMedPubMedCentralCrossRef
62.
Eichner LJ, Perry MC, Dufour CR, Bertos N, Park M, St-Pierre J, Giguere V (2010) miR-378(*) mediates metabolic shift in breast cancer cells via the PGC-1beta/ERRgamma transcriptional pathway. Cell Metab 12(4):352–361PubMedCrossRef
63.
Serguienko A, Grad I, Wennerstrom AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O, Munthe E (2015) Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA Oncotarget 6(4):2451–2465PubMedCrossRef
64.
Favaro E, Ramachandran A, McCormick R, Gee H, Blancher C, Crosby M, Devlin C, Blick C, Buffa F, Li JL et al (2010) MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS ONE 5(4):e10345PubMedPubMedCentralCrossRef
65.
Tsukerman P, Stern-Ginossar N, Gur C, Glasner A, Nachmani D, Bauman Y, Yamin R, Vitenshtein A, Stanietsky N, Bar-Mag T et al (2012) MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. Cancer Res 72(21):5463–5472PubMedCrossRef
66.
Shen J, Pan J, Du C, Si W, Yao M, Xu L, Zheng H, Xu M, Chen D, Wang S et al (2017) Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer. Cell Death Dis 8(4):e2740PubMedPubMedCentralCrossRef
67.
Elias S, Mandelboim O (2012) Battle of the midgets: innate microRNA networking. RNA Biol 9(6):792–798PubMedCrossRef
68.
Dinami R, Ercolani C, Petti E, Piazza S, Ciani Y, Sestito R, Sacconi A, Biagioni F, le Sage C, Agami R et al (2014) miR-155 drives telomere fragility in human breast cancer by targeting TRF1. Cancer Res 74(15):4145–4156PubMedCrossRef
69.
Czochor JR, Sulkowski P, Glazer PM (2016) miR-155 overexpression promotes genomic instability by reducing high-fidelity polymerase delta expression and activating error-prone DSB repair. Mol Cancer Res 14(4):363–373PubMedPubMedCentralCrossRef
70.
Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K, Weinstock DM et al (2011) miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 41(2):210–220PubMedCrossRef
71.
Choi YE, Pan Y, Park E, Konstantinopoulos P, De S, D’Andrea A, Chowdhury D (2014) MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability. Elife 3:e02445PubMedPubMedCentralCrossRef
72.
Moazzeni H, Najafi A, Khani M (2017) Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol Cell Probes 34:45PubMedCrossRef
73.
Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, Chen H, Lu X (2010) Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res 70(18):7176–7186PubMedPubMedCentralCrossRef
74.
Xiang M, Birkbak NJ, Vafaizadeh V, Walker SR, Yeh JE, Liu S, Kroll Y, Boldin M, Taganov K, Groner B et al (2014) STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-kappaB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal 7(310):ra11PubMedPubMedCentralCrossRef
75.
Bahena-Ocampo I, Espinosa M, Ceballos-Cancino G, Lizarraga F, Campos-Arroyo D, Schwarz A, Garcia-Lopez P, Maldonado V, Melendez-Zajgla J (2016) miR-10b expression in breast cancer stem cells supports self-renewal through negative PTEN regulation and sustained AKT activation. EMBO Rep 17(7):1081PubMedPubMedCentralCrossRef
76.
77.
Luo Q, Li X, Gao Y, Long Y, Chen L, Huang Y, Fang L (2013) MiRNA-497 regulates cell growth and invasion by targeting cyclin E1 in breast cancer. Cancer Cell Int 13(1):95PubMedPubMedCentralCrossRef
78.
Mandujano-Tinoco EA, Garcia-Venzor A, Munoz-Galindo L, Lizarraga-Sanchez F, Favela-Orozco A, Chavez-Gutierrez E, Krotzsch E, Salgado RM, Melendez-Zajgla J, Maldonado V:(2017) miRNA expression profile in multicellular breast cancer spheroids. Biochim Biophys Acta 1864:1642PubMedCrossRef
79.
Pan Y, Li J, Zhang Y, Wang N, Liang H, Liu Y, Zhang CY, Zen K, Gu H (2016) Slug-upregulated miR-221 promotes breast cancer progression through suppressing E-cadherin expression. Sci Rep 6:25798PubMedPubMedCentralCrossRef
80.
Gao S, Wang Y, Wang M, Li Z, Zhao Z, Wang RX, Wu R, Yuan Z, Cui R, Jiao K et al (2017) MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer. Oncotarget 8:41451PubMedPubMedCentral
81.
Ivancich M, Schrank Z, Wojdyla L, Leviskas B, Kuckovic A, Sanjali A, Puri N (2017) Treating cancer by targeting telomeres and telomerase. Antioxidants 6(1):E15PubMedCrossRef
82.
Bacci M, Giannoni E, Fearns A, Ribas R, Gao Q, Taddei ML, Pintus G, Dowsett M, Isacke CM, Martin LA et al (2016) miR-155 drives metabolic reprogramming of ER+ breast cancer cells following long-term estrogen deprivation and predicts clinical response to aromatase inhibitors Cancer Res 76(6):1615–1626PubMedCrossRef
83.
Lei K, Du W, Lin S, Yang L, Xu Y, Gao Y, Xu B, Tan S, Xu Y, Qian X et al (2016) 3B, a novel photosensitizer, inhibits glycolysis and inflammation via miR-155-5p and breaks the JAK/STAT3/SOCS1 feedback loop in human breast cancer cells. Biomed Pharmacother 82:141–150PubMedCrossRef
84.
Williams M, Cheng YY, Blenkiron C, Reid G:(2016) Exploring mechanisms of MicroRNA downregulation in cancer. Microrna 6:2CrossRef
85.
86.
Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR (2010) Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol 4(3):255–266PubMedPubMedCentralCrossRef
87.
Berton S, Cusan M, Segatto I, Citron F, D’Andrea S, Benevol S, Avanzo M, Dall’Acqua A, Schiappacassi M, Bristow RG et al (2017) Loss of p27kip1 increases genomic instability and induces radio-resistance in luminal breast cancer cells. Sci Rep 7(1):595PubMedPubMedCentralCrossRef
88.
Selcuklu SD, Yakicier MC, Erson AE (2009) An investigation of microRNAs mapping to breast cancer related genomic gain and loss regions. Cancer Genet Cytogenet 189(1):15–23PubMedCrossRef
89.
90.
Sun H, Ding C, Zhang H, Gao J (2016) Let7 miRNAs sensitize breast cancer stem cells to radiation-induced repression through inhibition of the cyclin D1/Akt1/Wnt1 signaling pathway. Mol Med Rep 14(4):3285–3292PubMedCrossRef
91.
Andorfer CA, Necela BM, Thompson EA, Perez EA (2011) MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med 17(6):313–319PubMedCrossRef
92.
Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC, Ding WQ (2016) Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res 18(1):90PubMedPubMedCentralCrossRef
93.
Liu B, Su F, Chen M, Li Y, Qi X, Xiao J, Li X, Liu X, Liang W, Zhang Y et al (2017) Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer. Hum Pathol 64:44PubMedCrossRef
94.
Han JG, Jiang YD, Zhang CH, Yang YM, Pang D, Song YN, Zhang GQ (2017) A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer. Ann Surg Treat Res 92(2):55–66PubMedPubMedCentralCrossRef
95.
Mangolini A, Ferracin M, Zanzi MV, Saccenti E, Ebnaof SO, Poma VV, Sanz JM, Passaro A, Pedriali M, Frassoldati A et al (2015) Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR. Biomark Res 3:12PubMedPubMedCentralCrossRef
96.
Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H, Horiguchi J (2017) Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. J Hum Genet 62(1):15–24PubMedCrossRef
97.
Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL et al (2014) microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget 5(5):1174–1184PubMedPubMedCentralCrossRef
98.
Fkih MI, Privat M, Trimeche M, Penault-Llorca F, Bignon YJ, Kenani A miR-10b, miR-26a, miR-146a and miR-153 expression in triple negative vs non triple negative breast cancer: potential biomarkers. Pathol Oncol Res 23:815
99.
Tsang JY, Ni YB, Ng EK, Shin VY, Mak KF, Go EM, Tawasil J, Chan SK, Ko CW, Kwong A et al (2015) MicroRNAs are differentially deregulated in mammary malignant phyllodes tumour. Histopathology 67(3):294–305PubMedCrossRef
100.
Raychaudhuri M, Bronger H, Buchner T, Kiechle M, Weichert W, Avril S (2017) MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 162(3):511–521PubMedPubMedCentralCrossRef
101.
Halvorsen AR, Helland A, Gromov P, Wielenga VT, Talman MM, Brunner N, Sandhu V, Borresen-Dale AL, Gromova I, Haakensen VD (2017) Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer. Mol Oncol 11(2):220–234PubMedCrossRef
102.
Das S, Lin TS (2016) The role of MicroRNAs in diagnosis, prognosis, metastasis and resistant cases in breast cancer. Curr Pharm Des 23:1845
103.
Radulovic V, Heider T, Richter S, Moertl S, Atkinson MJ, Anastasov N (2017) Differential response of normal and transformed mammary epithelial cells to combined treatment of anti-miR-21 and radiation. Int J Radiat Biol 93(4):361–372PubMedCrossRef
104.
Zhao D, Tu Y, Wan L, Bu L, Huang T, Sun X, Wang K, Shen B (2013) In vivo monitoring of angiogenesis inhibition via down-regulation of mir-21 in a VEGFR2-luc murine breast cancer model using bioluminescent imaging. PLoS ONE 8(8):e71472PubMedPubMedCentralCrossRef
105.
Zhong S, Li W, Chen Z, Xu J, Zhao J (2013) MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene 531(1):8–14PubMedCrossRef
106.
Shen R, Wang Y, Wang CX, Yin M, Liu HL, Chen JP, Han JQ, Wang WB (2015) MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer. Am J Transl Res 7(10):2115–2126PubMedPubMedCentral
107.
Zhao G, Li Y, Wang T (2017) Potentiation of docetaxel sensitivity by miR-638 via regulation of STARD10 pathway in human breast cancer cells. Biochem Biophys Res Commun 487(2):255–261PubMedCrossRef
108.
Zhang N, Wang X, Huo Q, Sun M, Cai C, Liu Z, Hu G, Yang Q (2014) MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin. Oncogene 33(24):3119–3128PubMedCrossRef
109.
Li LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou X, Zhang ZJ, Peng YH, Yang YZ, Yun JP (2014) miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. Carcinogenesis 35(2):469–478PubMedCrossRef
110.
Rupaimoole R, Slack FJ (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16(3):203–222PubMedCrossRef
111.
Thomson DW, Dinger ME (2016) Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet 17(5):272–283PubMedCrossRef
112.
Welch JD, Baran-Gale J, Perou CM, Sethupathy P, Prins JF (2015) Pseudogenes transcribed in breast invasive carcinoma show subtype-specific expression and ceRNA potential. BMC Genom 16:113CrossRef
113.
114.
Hou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y, Zhao L, Zhang Y, Huang B, Lu J (2014) LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis 5:e1287PubMedPubMedCentralCrossRef
115.
Huan J, Xing L, Lin Q, Xui H, Qin X (2017) Long noncoding RNA CRNDE activates Wnt/beta-catenin signaling pathway through acting as a molecular sponge of microRNA-136 in human breast cancer. Am J Transl Res 9(4):1977–1989PubMedPubMedCentral
116.
Metadata
Title
New emerging roles of microRNAs in breast cancer
Authors
Edna Ayerim Mandujano-Tinoco
Alfredo García-Venzor
Jorge Melendez-Zajgla
Vilma Maldonado
Publication date
01-09-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4850-7

Other articles of this Issue 2/2018

Breast Cancer Research and Treatment 2/2018 Go to the issue

Clinical trial

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

Clinical trial

Intratumoral heterogeneity on dedicated breast positron emission tomography predicts malignancy grade of breast cancer

Epidemiology

Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes

Epidemiology

Extent of regional lymph node surgery and impact on outcomes in patients with early-stage breast cancer and limited axillary disease undergoing mastectomy

Epidemiology

Evolving surgical treatment decisions for male breast cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database

Preclinical study

Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: a retrospective analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits